

Xibax

etoricoxib 60mg, 90mg and 120mg

Safe & Effective
in Relieving
Chronic Pain



 **Avalon Pharma**

Xibax

etoricoxib 60mg, 90mg and 120mg

Safe & Effective

in Relieving Chronic Pain

Xibax

etoricoxib 60mg, 90mg and 120mg

shows profound improvement in osteoarthritis pain

Most effective treatment within
a range of alternatives

Etoricoxib is the most likely to show the greatest
improvements in pain and physical function. (Figure 1)




Fig. (1). Probability that each treatment provides the greatest improvements in pain, physical function and PGADS. (PGADS: patient global assessment of disease status)

Xibax

etoricoxib 60mg, 90mg and 120mg

possess a distinctive advantage within the COXIB Class

Selectivity

XIBAX (Etoricoxib) shows higher binding affinity towards receptor vs Celecoxib¹

Early Efficacy

XIBAX (Etoricoxib) shows rapid onset of action in comparison to Celecoxib
Early efficacy within the first 4 hrs¹ | Onset of symptomatic relief within 24 to 48 hrs^{1,2}

Prolonged Activity

XIBAX (Etoricoxib) sustains efficacy for prolonged duration up to 27 h¹

Sustained Analgesia

Just 14 days of XIBAX (Etoricoxib) significantly improves pain that is sustained
till 52 weeks^{3,4}

Convenience

XIBAX (ETORICOXIB)
daily dose



CELECOXIB
daily dose



Tolerability

XIBAX (Etoricoxib) exhibits minimal patient withdrawals due to lack of
efficacy or adverse events⁵

 **Avalon Pharma**

Middle East Pharmaceutical Industries Co. Ltd.

P.O. Box 301332 Riyadh 11372

Tel: +966 11 464 3924

Fax: +966 11 462 0471

Email: info@avalon.com.sa avalonpharmaceutical.com

1. Etoricoxib SPC & Celecoxib SPC
2. Zacher J, Feldman D, Gerli R, et al. 2003. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. *Curr Med Res Opin*. 19:725-36.
3. Moss D, Benson H, A. E., Will R, & Wright, A. (2007). Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trial. *Osteoarthritis and Cartilage*, 25(8), 1781-1791.
4. Curtis SD, Bockle B, Fisher C, O'Leary J, Compton A, Jay A, Dacin AS. Etoricoxib in the treatment of osteoarthritis over 52 weeks: a double-blind, active-comparator controlled trial (NCT00242489). *BMC Musculoskeletal Disord*. 2005 Dec 16:6.
5. Song G-G, Seo Y-H, Kim JH, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis. *Z Rheumatol* 75, 508-516 (2016).
6. Starn W, Jansen J, Taylor S. Efficacy of etoricoxib, celecoxib, lumiracoxib, non-selective NSAIDs, and acetaminophen in osteoarthritis: a mixed treatment comparison. *Open Rheumatol J*. 2012;6:6-20.